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Abstract
Since 2013 next-generation sequencing (NGS) targeting genes mutated in diffuse gliomas is part of routine
diagnostics in our institute. In the present report, we evaluate the use of this custom tailored NGS platform on 434
samples. The NGS panel assesses mutations in ATRX, CIC, EGFR, FUBP1, NOTCH1, PTEN; H3F3A, IDH1/2, PIK3CA, and
BRAF, amplifications in EGFR or MDM2 and copy number alterations (CNA) of chromosome 1p, 7, 10 and 19q. TERT
promoter mutations were assessed separately when indicated. Of the 433 samples of individual tumors with NGS
data available, 176 cases were diagnosed as grade 2 or 3 glioma (40.6) and in 201 patients a glioblastoma (46.4%).
Of the remaining 56 patients, 22 had inconclusive histology. In 378 cases (87.1%) a diagnosis solely based on
glioma-targeted NGS could be established and resulted in a different diagnosis in ~ 1/4 of the cases. In 17 out of
22 cases without a conclusive histological diagnosis NGS resulted in a molecular diagnosis.
The current study on a large cohort of patients confirms the diagnostic strength of the platform we developed,
with a clear separation of glioma subgroups with different outcomes. It demonstrates the diagnostic value and the
efficiency of glioma-targeted NGS for routine glioma diagnostics allowing with a single assay a glioma diagnosis in
the large majority of cases. It allows in one run the molecular assessments required for the WHO classification of
diffuse gliomas, including the recent recommendations to assess copy number alterations of chromosome 7 and
10, and of the TERT promoter region in IDHwt lower grade glioma.
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Introduction
In 2016 a major revision of the WHO classification for tu-
mors of the central nervous system was implemented [6].
The main adjustment was the incorporation of molecular
criteria to the diagnostic classification. In adult diffuse gli-
oma this is now centered around isocitrate dehydrogenase
(IDH) and 1p/19q diagnostics. However, several other
markers are potentially relevant for routine testing, in-
cluding assessment of copy number alterations (CNA) of
chromosome 7 and 10, (homozygous) CDKN2A loss, and
mutations in the TERT promoter or BRAF and H3F3A
genes [14, 20]. Previous studies have shown that molecular
characteristics do not only hold a diagnostic value, but
also can give more detailed information about prognosis.
An example is the significant worse overall survival of pa-
tients with a grade II glioma with an IDH-wildtype tumor
with gain of chromosome 7 and loss of chromosome 10 or
with TERT mutations compared to those with an IDH--
wildtype tumor without these lesions [1, 13, 16, 18, 21].
Another study also identified PI3-kinase mutations as
markers of poor prognosis in IDH-mutated andATRX/
TP53 mutated diffuse gliomas, median survival 3.7 v. 6.3
years (P = 0.02) [7].
Since 2013, in our institute a next-generation sequen-
cing (NGS) panel targeting genes frequently mutated in
gliomas is part of routine diagnostics. We previously
showed that this approach identified clinically relevant
glioma subgroups by analysis of historical samples ob-
tained in the EORTC trial on PCV chemotherapy of
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anaplastic oligodendroglial tumors, with a very low fail-
ure rate [8]. We also demonstrated that the use of single
nucleotide polymorphisms (SNP’s) in this panel allows
the reliable assessment of CNA’s [9]. In the present re-
port we evaluate retrospectively the routine use of this
custom tailored NGS platform in everyday clinical prac-
tice, to assess whether it allows us to diagnose patients
accurately and efficiently.
Materials and methods
We included all patients from whom glioma-targeted
NGS data were available between 2013 and March 17th
2017, during which period all findings were routinely en-
tered into a database. As part of the present evaluation
of this diagnostic platform, we added clinical, demo-
graphic and survival information. Since many patients
were referred from other institutions with limited data
on the clinical course, the date of the first (diagnostic)
surgery was used as the date of diagnosis and survival
was measured from this date. The principle aims of this
study were to describe and evaluate the routine use and
additional value of glioma targeted NGS, with emphasis
on cases without a histological diagnosis or without a
molecular diagnosis, on histological grade II and III IDH
wild type glioma.
In the first phase after introduction of the targeted
NGS panel, the platform was routinely used for all grade
II and III gliomas, all cases with oligodendroglial hist-
ology, patients with a diagnosis of a glioblastoma below
the age of 51, all diagnostic challenging cases and cases
in which the histological diagnosis was reviewed. Follow-
ing the introduction of the WHO 2016 criteria, the
upper age limit for routine testing of glioblastoma was
increased to 55 years of age and currently includes im-
munohistochemistry for IDH R132H mutations in glio-
blastoma patients over that age [15, 23]. In addition,
because of actively recruiting clinical trials in glioblast-
oma with either amplification of EGFR, MET, or MDM2
or mutations in PTEN, or BRAF, patients potentially eli-
gible for these trials were also investigated. TERT pro-
moter mutations were assessed separately in cases in
which it was considered clinically indicated (grade 2 and
3 astrocytoma IDHwt) using SNAPSHOT analysis [11]
as described previously. The used NGS panel assesses
mutations in ATRX, CIC, EGFR, FUBP1, NOTCH1,
PTEN; H3F3A, IDH1/2, PIK3CA and BRAF; amplifica-
tions in EGFR, MDM2 and MET and CNA’s of chromo-
some 1p, 19q, 10 and 7 as described elsewhere [8, 9, 16].
Analysis of MDM2 and MET amplification were added
later once trials were activated that required these as in-
clusion criteria, and after validation of the assay by
FISH. The limit of detection of SNP analysis for loss of
heterozygosity determination has been shown to be ap-
proximately 20% of tumor cells [9]. The panel was
further modified in March 2017 to include more SNP’s
for assessment of additional CNA’s (incl 9p, 17) and mu-
tations more relevant for childhood brain tumors. No
patients tested after this modification of the panel were
included in the present series.
Criteria for the molecular diagnosis of diffuse glioma
were defined as follows:
– molecular astrocytoma: IDH mutation, without 1p/
19q co-deletion.
– molecular oligodendroglioma: IDH mutation with
1p/19q co-deletion
– molecular glioblastoma: IDH1/2 wildtype with either
TERT promoter mutation, 7+/10- or EGFR
amplification
– Midline and hemispheral tumors with H3F3A
mutations: H3F3A mutation, subdivided in H3F3A
K27M and H3F3A G34M mutated tumors based on
the specific mutation present.
– BRAF-mutated tumors (although not a clinical entity
they are reported separately in view of potential
treatment implications)
The panel is not designed to identify fusion genes (eg,
the BRAF-KIAA fusion gene). The molecular diagnosis
is only made in the presence of positive findings with
the NGS panel, not on histology. Survival plots were
made for cumulative mortality of all diagnostic groups.
Histologically diagnosed glioblastoma were stratified in 2
molecular subgroups based on the presence or absence
of IDH1/2 mutation. Patients who did not reach an end-
point before follow-up ended were censored based on
the date they were last seen. Logrank was used to com-
pare survival between groups; a p-value below 0.05 was
considered significant. The statistical analysis was done
using SPSS 24 for Windows.
Results
In total we included 441 NGS samples (March 2013 –
March 2017), from 432 patients. In 9 patients two sam-
ples were obtained at different time points. One patient
with an oligodendroglioma developed a second tumor
outside the field of the primary lesion, which appeared
on imaging more consistent with a glioblastoma. NGS
confirmed the presence of two different entities (1 oligo-
dendroglioma and 1 glioblastoma). Both lesions from
this patient were included in the analysis. In none of the
other 8 patients NGS of a sample obtained at progres-
sion resulted in a reclassification of the tumor compared
to analysis of the earlier sample. The following results
are based on the 433 NGS samples of individual tumors.
In 176 out of 433 cases (40.6%) there was a histological
diagnosis of a grade 2 or 3 tumor and in 201 patients a
glioblastoma (46.4%), Table 1 details the histological
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findings. In 377 out of 433 cases (87.1%) a diagnosis
solely based on the molecular diagnostics could be
established (Table 2). In 17 of 22 cases (5.1%) without a
conclusive histological diagnosis NGS resulted in a mo-
lecular tumor diagnosis (77.3%): 3 were diagnosed with
oligodendroglioma (13.6%), 2 with astrocytoma (9.1%),
11 with glioblastoma (50.0%) and 1 with a BRAF-mu-
tated tumor (4.5%). Moreover, in 8 of these 22 cases the
pathologist did not find evidence of a tumor, whereas
the NGS panel found a glioblastoma in 4 patients, an
oligodendroglioma in 1 patient and a BRAF-mutated
tumor in 1 patient (Additional file 1: Figure S1 and Add-
itional file 2: Figure S2). In the 2 remaining cases in
which the pathologist did not find evidence of a tumor
no molecular aberrations were detected and no conclu-
sive evidence for a tumor was obtained. One of these
cases was diagnosed with an autoimmune encephalitis
and treated accordingly, the other is lost to follow-up. In
15 out of 433 cases (3.5%) a BRAF-mutation was found
and in 12 out of 433cases (2.8%) an H3F3A-mutated
tumor (K27M: 9 (2.1%), G34M: 3 (0.7%)). In 123 out of
433 cases (28.4%) molecular characterization led to a
change of diagnosis (without taking tumors with BRAF
or H3F3A mutations into account). Additional file 3:
Table S1 presents an overview of the histological diagno-
ses and the molecular diagnosis that were made in each
histopathological category.
Out of 19 cases (4.4%) in which no mutations or CNA
at all were detected by NGS analysis, there was a histo-
pathological diagnosis in 15 cases (78.9%) of which 4 were
pilocytic astrocytoma (including 1 pilomyxoid astrocy-
toma), 4 astrocytoma, 2 ependymoma, 1 oligodendrogli-
oma, 1 neurocytoma, 1 medulloblastoma, 1 ganglioglioma
and 1 desmoplastic infantile astrocytoma; in 1 case histo-
logical evaluation revealed only radionecrosis.
In Table 3 an overview can be seen of the prevalence
of TP53, FUBP1, CIC, ATRX, PTEN, NOTCH1 and
PIK3CA mutations specified for each molecular diagno-
sis. As expected, ATRX and TP53 mutations were seen
in most astrocytomas, and CIC and FUBP1-mutation
were observed in oligodendrogliomas.
Of the 433 patients analyzed, 231 (53.3%) had died at the
time of this analysis. Survival based on molecular diagnosis
showed a median survival of 9.6 years of patients with as-
trocytoma, 15.1 years of patients with oligodendroglioma,
1.5 years of patients with glioblastoma, 5.2 years of patients
with BRAF-mutated tumors, 1.5 years of patients with
H3F3A K27M-mutated tumors (n = 9) and 2.7 years of pa-
tients with H3F3A G34M-mutated tumors (n = 3) (Fig. 2).
Patients without any detectable mutation (n = 19/433) had
a median overall survival of 12.8 years in contrast to 2.4
years median survival of patients with mutations that did
however not allow a classification (n = 37) (Fig. 1). In tu-
mors that were histologically diagnosed as glioblastoma,
IDHwt tumors (molecular glioblastoma) had a significantly
worse survival in comparison to IDHmt tumors (median
overall survival 1.6 vs 7.5 years; logrank p < 0.001) (Fig. 2).
For this comparison we excluded 3 out of 201 histological
glioblastoma which were reclassified as oligodendroglioma
and 7 which were reclassified as H3F3A-mutated tumors.
Patients with a histologically diagnosed astrocytoma IDHmt
had a median overall survival of 13.7 years; those with an
anaplastic astrocytoma IDHmt 8.4 years and glioblastoma
IDHmt 7.5 years (logrank 0.038 for the difference between
astrocytoma and glioblastoma) (Fig. 3).
MET and MDM2 amplifications were seen in 3 out of 78
(3.8%) and 17 out of 110 cases (15.5%) molecular glioblast-
omas respectively tested for these amplifications. EGFR am-
plifications were observed in 83 out of the 179 cases
(46.4%). Survival analysis did not show a distinct survival
difference between molecular glioblastoma patients with or
without MET, MDM2 or EGFR amplifications (logrank p =
0,997; p = 0,478; p = 0.181 respectively) (Fig. 4).
Discussion
This evaluation of our molecular data confirms the great
value of glioma targeted NGS for routine brain tumor
Table 1 Histological diagnosis
Number of cases (%)
Inconclusive 22 (5.1)
Astrocytoma 83 (19.2)
Anaplastic astrocytoma 38 (8.8)
Oligoastrocytoma 5 (1.2)
Anaplastic oligoastrocytoma 6 (1.4)
Oligodendroglioma 30 (6.9)
Anaplastic oligodendroglioma 14 (3.2)
Glioblastoma 201 (46.4)
Ganglioglioma 6 (1.4)
Pilocytic astrocytoma 9 (2.1)
Other 19 (4.1)
Total 433
Table 2 Molecular diagnosis
Number of cases (%)
No mutations identified 19 (4.4)
Unclassifying mutations 37 (8.5)
Astrocytoma 117 (27.0)
Oligodendroglioma 54 (12.5)
Glioblastoma 179 (41.3)
H3F3A K27 M-mutated tumor 9 (2.1)
H3F3A G34 M-mutated tumor 3 (0.7)
BRAF-mutated tumor 15 (3.5)
Total 434
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diagnostics. Our Ion Torrent based NGS panel allows
simultaneous assessment of a number of mutations and
CNA that are relevant for gliomas. We introduced this
platform into routine diagnostics once a validation series
showed an improved classification and prognostication
of the NGS panel in comparison to classical histopath-
ology, which finding has been confirmed by other series
[10, 19, 22]. The improved classification of gliomas using
molecular criteria resulted in to the major 2016 revision
of the WHO criteria for brain tumors [6]. The current
study on a large cohort of patients underscores the diag-
nostic strength of the platform we developed, with a
clear separation of glioma subgroups with different
outcomes consistent with our findings in the earlier
study on EORTC study 26,951 [8].
Although results of NGS in diffuse glioma have been
published before, none of these other studies showed data
on the diagnostic value of the NGS panel in cases in which
no diagnosis could be established based on the histological
findings, nor did they include survival information. Several
studies found a high sensitivity of NGS panels to detect
genetic alterations known to be present by conventional
techniques [17, 19, 22]. Zacher et al. also used a 20-gene
panel for an integrated histological and molecular diagno-
sis of 111 diffuse gliomas, allowing reclassification of oli-
goastrocytoma and glioblastoma by IDH-status and
Table 3 Overview of prevalence of specific mutations specified for each molecular diagnosis
Molecular diagnosis TP53 FUBP1 CIC ATRX PTEN NOTCH1 PIK3CA
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Astrocytoma 114 (97.4) 1 (0.9) 3 (2.6) 85 (72.6) 6 (5.1) 9 (7.7) 1 (0.9)
Oligodendroglioma 3 (5.6) 15 (27.8) 26 (48.1) 2 (3.7) 5 (9.3) 7 (13.0) 3 (5.6)
Glioblastoma 45 (25.1) 0 (0) 7 (3.9) 6 (3.4) 81 (45.3) 8 (4.5) 2 (1.1)
H3F3A K27 M-mutated tumor 7 (77.8) 1 (11.1) 0 (0) 1 (11.1) 1 (11.1) 1 (11.1) 1 (10.0)
H3F3A G34 M-mutated tumor 3 (100) 0 (0) 1 (33.3) 3 (100) 0 (0) 0 (0) 0 (0)
BRAF-mutated tumor 1 (6.7) 1 (6.7) 1 (6.7) 0 (0) 0 (0) 1 (6.7) 1 (6.7)
Unclassifying mutations 10 (27.0) 1 (2.7) 1 (2.7) 7 (18.9) 8 (21.6) 3 (8.1) 2 (5.4)
Fig. 1 Survival curves for all patients based on the molecular diagnosis
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identification of tumors with H3F3A mutations [22].
Ballester et al. used a more extensive NGS panel (46–50
genes) in 381 brain tumors and found that the most clinic-
ally relevant genes for brain tumor classification in their
panel were IDH1, IDH2, TP53, PIK3CA, BRAF, EGFR,
PDGFRA and FGFR1/2/3. Sahm et al. [12] found that in-
formation derived from their NGS protocol identified po-
tential targets for experimental therapy (i.e. EGFR, BRAF,
PTEN in 37/47 (79%) glioblastomas, 9/10 (90%) pilocytic
astrocytomas, and 5/14 (36%) medulloblastomas in a pro-
spective cohort (n = 71) [22]. This is in line with our re-
sults, although it is fair to say that at present only BRAF
V600E mutations represent a validated target for precision
medicine (Table 3).
A major advantage of a glioma-targeted NGS approach
like this panel is the simultaneous detection of several
markers relevant for glioma diagnostics, including copy
number alterations, allowing glioma diagnostics according
to the revised WHO 2016 classification. These can each
be individually assessed by other tests (eg, immunohisto-
chemistry, FISH, Sanger sequencing) and then usually car-
ried out sequentially but that makes the diagnostic
process more time consuming. Although NGS may be a
relatively expensive diagnostic method, it yields with one
assay information that otherwise would require several
tests. Moreover, the costs of NGS are rapidly decreasing
making it more affordable. Also, the test can be done on
very limited amounts of tissue (minimal requirement is 1
Fig. 2 Survival curves for all histological glioblastoma based on IDH mutation status
Fig. 3 Survival curves for IDHmt tumor based on histological diagnosis (astrocytoma, anaplastic astrocytoma or glioblastoma)
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ng of DNA from approximately 150 cells consisting of at
least 30% neoplastic cells), independent of the method by
which the tissue has been obtained; ie. resection, biopsies
or even cytology.
The routine assessment of potentially actionable muta-
tions that may have implications for prognosis and treat-
ment is another argument for the routine use of NGS in
glioma. BRAF mutations are in particular interesting con-
sidering their potential treatment implications. Although
BRAF mutations are no part of the WHO classification and
not tumor specific, they are present in certain glioma sub-
types with an increased rate and have potentially clinical
implications since drugs are available that are active against
some BRAF mutations (in particular the BRAF V600E mu-
tation). We have been taken by surprise in several cases
where despite a histological diagnosis without an increased
likelihood of a BRAF mutation a BRAF V600E mutation
was identified. Another major advantage is the further clas-
sification of grade II and III IDHwt astrocytomas, of which
some have molecular features that allow them to be classi-
fied as glioblastoma, holding prognostic and treatment im-
plications [2, 14]. The recently published 3rd paper of the
cIMPACT-NOW committee for the integration of new in-
formation into the classification of brain tumors now rec-
ommends to classify IDHwt grade II or III astrocytoma
with either high level EGFR amplification, or whole
chromosome 7 gain in combination with whole
chromosome 10 loss, or TERT promoter mutation as ‘dif-
fuse astrocytic glioma, IDH-wildtype, with molecular fea-
tures of glioblastoma, WHO grade IV’ [4]. This is similar to
the criteria we used for the diagnosis ‘molecular glioblast-
oma’. Vice versa, our data confirm the clear difference in
prognosis between IDHmt and IDHwt glioblastoma. The
median OS in our IDHmt glioblastoma possibly reflects a
bias towards performing NGS in glioblastoma patients with
an unusual long survival. There is also evidence suggesting
homozygous deletion of CDKN2A/B identifies poor prog-
nosis IDHmt astrocytoma [2]. This finding and the 3rd
cIMPACT-NOW report underscore the diagnostic import-
ance of the routine use of a panel that simultaneously as-
sesses glioma relevant mutations and more copy number
alterations than only 1p and 19q.
The routine use of an NGS panel still requires a critical
evaluation of the clinical, radiological features and histo-
pathological findings in the case under consideration. In
our series, a mistake almost made was the diagnosis of a
molecular glioblastoma in a fossa posterior tumor in a
young patient with histological characteristics of a medul-
loblastoma (7+/10-, TERT +). These alterations can how-
ever also be found in medulloblastoma. Also, independent
of the technique used there is always the possibility of in-
conclusive findings. In a few cases indeed no molecular
diagnosis was obtained. In most of these cases rare brain
tumors without a typical molecular profile were diagnosed
A
C
B
Fig. 4 Survival curves for molecular glioblastoma based on (a) MET, (b) MDM2 and (c) EGFR amplification status
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histopathologically. The opposite also happened: cases in
which the histopathology remained inconclusive or failed
to identify tumor whereas the NGS panel yielded a clear
diagnosis. The most impressive experiences were of
course the 6 cases in which the pathologist was unable to
positively identify tumor but in which a very characteristic
mutation and/or CNA pattern associated with glioma was
identified, even from biopsy samples. This has of course a
major clinical impact for patients.
Early 2017 the platform has been revised and ex-
panded, to allow detection of mutations in de TERT pro-
moter, in genes important for pediatric brain tumors and
other adult non-glioma brain tumors and more CNA’s
(including 9p, 17) that are relevant for pediatric, adoles-
cents and young adults. Clearly, platforms like this are a
moving target, and require the reconsideration of their
design with new information being reported. The diag-
nostic specificity also depends on the specificity of the
mutations and CNA’s identified within the histological
context (eg. H3F3A K27M mutations have now also
been identified in cases of less aggressive circumscript
fossa posterior lesions [5], BRAF mutations are not spe-
cific for a diagnostic category).
NGS is primarily aiming at mutations and allows sim-
ultaneous assessment of copy number alterations or of
fusion genes, depending on the used technology. There
is an increasing interest in the use of DNA genome wide
methylation based classification of central nervous sys-
tem tumors, which diagnostic sensitivity and clinical
usefulness has been demonstrated in a recent series [3].
Each of those more broad molecular diagnostic panels
have the major advantage of assessing more than one
molecular feature, resulting in more in depth diagnos-
tics. Obviously, any new version of these diagnostic
panels needs to be well validated before it is introduced
into routine clinical diagnostics. Ideally, this requires the
close collaboration of pathologists, molecular biologists
and clinicians at all stages of that process.
Limitations of the study are the testing of selected pa-
tients, in part of tertiary referrals and on clinical indica-
tions (eg, screening for trials targeted trails with targeted
agents, long term glioblastoma survivors). Also, germline
DNA was not investigated, which is less of an issue in case
of targeted NGS but still requires the distinction between
DNA variants without clinical significance and tumori-
genic mutations. Next, the criteria for molecular glioblast-
oma are not required by the WHO 2016 classification
schema to call a glioblastoma, but were used by us to have
positive molecular criteria for glioblastoma, and in some
cases of histological glioblastoma these were not found.
Of note, the c-IMPACT-NOW 3rd update proposes the
exact same criteria for ‘molecular features of glioblast-
oma’. Also, typical molecular abnormalities of some en-
tities are not covered by our panel (e.g., fusion genes like
RELA fusion genes, relevant for supratentorial ependy-
moma, BRAF-KIAA fusion gene relevant for pilocytic as-
trocytoma, FGFR fusion genes, potentially targetable). At
the period studied TERT promoter mutations could not
be assessed with our panel, but testing for this mutation
has been added to the 2017 revised version of the panel.
Then, of some entities characteristic mutations are not yet
identified, for these methylation analysis may be better
suited (e.g., posterior fossa ependymoma).
Conclusions
Routinely using an NGS pattern allowing the simultaneous
assessment of several relevant markers is a reliable and effi-
cient way of diagnostics in brain tumors allowing a rapid
diagnosis according to the WHO 2016 classification of brain
tumors. It allows clinicians to evaluate the potential options
for targeted therapy and provides more specific prognostic
information. The flexibility of these platforms allow them to
be modified once novel scientific information becomes avail-
able or changes are made in the criteria. The recent addition
of gain of chromosome 7 and loss of chromosome 10 to the
WHO classification emphasize this further. Anticipating an
increasing role for molecular diagnostics in brain tumors
and costs for NGS to decrease, NGS and other molecular
broad panel diagnostics will become part of standard diag-
nostics of glioma in the near future.
Additional files
Additional file 1: Table S1. Histological diagnosis and the NGS
diagnoses subsequently made. (DOCX 21 kb)
Additional file 2: Figure S1a, b. A 69 year old female developed right
sided weakness, T1 weighted MR images after intravenous contrast
administration (a) showed an enhacing lesion in the left frontal region . A
first biopsy showed brain tissue only. A second biopsy revealed some
increasse in cell density with pleiomorphic cells and reactvie astrocytes,
considered atypical glial cells, possibly indicative of a glioma (b, H & E
stain, 100 x magnification). Next generation sequencing of this sample
showed EGFR amplification, loss of chromsome 10 and a mutation in the
PTEN gene (c.464A > G; p.Y155CF). (ZIP 771 kb)
Additional file 3: Figure S2a-c. A 38 year old female presented with
burn-out complaints and several episodes suggestive of partial seizures.
MR (Fluid Attenuated Inverse Recovery) images showed a small area of
increased signal intensity on T2 weighted MR images with unclear
boundaries and without contrast uptake (a). The lesion was resected, hist-
ology showed some cell increase without clear evidence of tumor (b, H &
E stain, 100 x magnification). IDH immunohistochemistry for the R132H
mutation did not show positivity in the examined region (c). On next
generation sequencing, an IDH mutation (c.395 > A;p.132H) was found
and a pattern suggestive of 1p/19q codeletion. The interpretation of the
copy number alterations was hampered by by the low tumor cell per-
centage. (ZIP 1435 kb)
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